JP2022523055A - Ｃｒｉｓｐｒ活性をモジュレートするための系および方法 - Google Patents

Ｃｒｉｓｐｒ活性をモジュレートするための系および方法 Download PDF

Info

Publication number
JP2022523055A
JP2022523055A JP2021543277A JP2021543277A JP2022523055A JP 2022523055 A JP2022523055 A JP 2022523055A JP 2021543277 A JP2021543277 A JP 2021543277A JP 2021543277 A JP2021543277 A JP 2021543277A JP 2022523055 A JP2022523055 A JP 2022523055A
Authority
JP
Japan
Prior art keywords
polynucleotide
crispr
nucleotide
sequence
cleavable linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523055A5 (https=
Inventor
リード ケルソ，
ジャレド カールソン－スティーヴァーマー，
サヒル ジョシ，
トラヴィス モーレス，
アナスタシア カディナ，
ジョン アンドリュー ザ セカンド ウォーカー，
Original Assignee
シンテゴ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンテゴ コーポレイション filed Critical シンテゴ コーポレイション
Publication of JP2022523055A publication Critical patent/JP2022523055A/ja
Publication of JP2022523055A5 publication Critical patent/JP2022523055A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021543277A 2019-01-25 2020-01-25 Ｃｒｉｓｐｒ活性をモジュレートするための系および方法 Pending JP2022523055A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962797122P 2019-01-25 2019-01-25
US62/797,122 2019-01-25
US201962876177P 2019-07-19 2019-07-19
US62/876,177 2019-07-19
US201962939553P 2019-11-22 2019-11-22
US62/939,553 2019-11-22
PCT/US2020/015127 WO2020154714A2 (en) 2019-01-25 2020-01-25 Systems and methods for modulating crispr activity

Publications (2)

Publication Number Publication Date
JP2022523055A true JP2022523055A (ja) 2022-04-21
JP2022523055A5 JP2022523055A5 (https=) 2023-02-02

Family

ID=71735803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543277A Pending JP2022523055A (ja) 2019-01-25 2020-01-25 Ｃｒｉｓｐｒ活性をモジュレートするための系および方法

Country Status (9)

Country Link
US (2) US11884918B2 (https=)
EP (1) EP3914714A4 (https=)
JP (1) JP2022523055A (https=)
KR (1) KR20210123309A (https=)
CN (1) CN113874503A (https=)
AU (1) AU2020210884A1 (https=)
CA (1) CA3127486A1 (https=)
GB (1) GB2597377A (https=)
WO (1) WO2020154714A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US20220411790A1 (en) * 2019-10-25 2022-12-29 The Johns Hopkins University A crispr-cas9 platform with an intrinsic off-switch and enhanced specificity
US20240200059A1 (en) * 2021-04-09 2024-06-20 Vor Biopharma Inc. Photocleavable guide rnas and methods of use thereof
CN114410752B (zh) * 2022-01-24 2024-06-25 华南师范大学 一种基于光控的CRISPR-Cas核酸检测试剂盒及检测方法
US20260103702A1 (en) * 2022-09-30 2026-04-16 Board Of Trustees Of Southern Illinois University Compositions and methods for crispr modulation
WO2024215715A2 (en) * 2023-04-11 2024-10-17 President And Fellows Of Harvard College Chemical ligation techniques

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513040A (ja) * 2004-09-21 2008-05-01 ザ スクリップス リサーチ インスティテュート 光調節型アミノ酸の遺伝コード付加
JP2009511053A (ja) * 2005-10-12 2009-03-19 ザ スクリップス リサーチ インスティテュート ファージ提示型ポリペプチドの選択的翻訳後修飾
JP2013521269A (ja) * 2010-03-05 2013-06-10 メディカル リサーチ カウンシル 遺伝的にコードされた光制御
WO2017131237A1 (ja) * 2016-01-30 2017-08-03 株式会社ボナック 人工単一ガイドｒｎａ及びその用途
WO2017217768A1 (ko) * 2016-06-15 2017-12-21 주식회사 툴젠 온타겟 및 오프타겟의 다중 타겟 시스템을 이용하는, 표적 특이적 유전자 가위 스크리닝 방법 및 이의 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US8158595B2 (en) 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
CA2689042A1 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
US7923562B2 (en) 2008-06-16 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Photocleavable linker methods and compositions
JP2011525180A (ja) 2008-06-16 2011-09-15 バインド バイオサイエンシズ インコーポレイテッド 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
EA201290497A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2013065827A1 (ja) * 2011-11-04 2013-05-10 国立大学法人埼玉大学 核酸リンカー
US9228207B2 (en) * 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US10093929B2 (en) * 2013-10-14 2018-10-09 Stc.Unm Modular RNA regulators and methods
US20150376586A1 (en) * 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
WO2016022866A1 (en) 2014-08-07 2016-02-11 Agilent Technologies, Inc. Cis-blocked guide rna
US9816080B2 (en) * 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
WO2016094874A1 (en) * 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
US9650617B2 (en) * 2015-01-28 2017-05-16 Pioneer Hi-Bred International. Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
JP2018515142A (ja) * 2015-05-15 2018-06-14 ダーマコン，インコーポレイテッド． Ｃａｓ９介在遺伝子編集用の合成シングルガイドｒｎａ
EP3353309A4 (en) * 2015-09-25 2019-04-10 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHOD FOR GENERIC EDITING
US20200291369A1 (en) 2016-03-11 2020-09-17 Erasmus University Medical Center Rotterdam Improved CRISPR-Cas9 Genome Editing Tool
EP3219799A1 (en) * 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
CN109415729B (zh) 2016-04-21 2022-12-09 生命技术公司 具有降低毒性的基因编辑试剂
EP3638789A4 (en) * 2017-06-12 2021-03-10 California Institute of Technology CONDITIONAL GUIDE RNAS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513040A (ja) * 2004-09-21 2008-05-01 ザ スクリップス リサーチ インスティテュート 光調節型アミノ酸の遺伝コード付加
JP2009511053A (ja) * 2005-10-12 2009-03-19 ザ スクリップス リサーチ インスティテュート ファージ提示型ポリペプチドの選択的翻訳後修飾
JP2013521269A (ja) * 2010-03-05 2013-06-10 メディカル リサーチ カウンシル 遺伝的にコードされた光制御
WO2017131237A1 (ja) * 2016-01-30 2017-08-03 株式会社ボナック 人工単一ガイドｒｎａ及びその用途
WO2017217768A1 (ko) * 2016-06-15 2017-12-21 주식회사 툴젠 온타겟 및 오프타겟의 다중 타겟 시스템을 이용하는, 표적 특이적 유전자 가위 스크리닝 방법 및 이의 용도

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACS CHEM. BIOL., vol. 12, JPN6023050873, 2017, pages 2183 - 2190, ISSN: 0005358218 *
ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 55, JPN5022003959, 2016, pages 12440 - 12444, ISSN: 0005358217 *
SYNTHESIS OF PHOTO- AND CHEMICAL-ACTIVATED NUCLEOSIDES AND UNNATURALAMINO ACIDS, JPN5022003967, 2014, pages 130 - 296, ISSN: 0005358219 *

Also Published As

Publication number Publication date
CA3127486A1 (en) 2020-07-30
US20240209356A1 (en) 2024-06-27
EP3914714A2 (en) 2021-12-01
CN113874503A (zh) 2021-12-31
KR20210123309A (ko) 2021-10-13
WO2020154714A2 (en) 2020-07-30
US11884918B2 (en) 2024-01-30
GB2597377A (en) 2022-01-26
AU2020210884A1 (en) 2021-08-12
EP3914714A4 (en) 2024-04-10
US20220073912A1 (en) 2022-03-10
GB202110534D0 (en) 2021-09-08
WO2020154714A3 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
US11884918B2 (en) Systems and methods for modulating CRISPR activity
JP7431891B2 (ja) 化学的に修飾されたガイドｒｎａを使用する高特異性ゲノム編集
US11667903B2 (en) Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/CAS9
ES2884838T3 (es) ARN guía químicamente modificados para la regulación génica mediada por CRISPR/CAS
US12139707B2 (en) Stabilized CRISPR complexes
US20240218354A1 (en) Guide rnas with chemical modification for prime editing
CN112585268A (zh) 通过插入供体多核苷酸用于基因组编辑的组合物和方法
JP4517061B2 (ja) ダンベル型ｄｎａの効率的な製造方法
US20230340468A1 (en) Methods for using guide rnas with chemical modifications
US20250302925A1 (en) Conjugated crispr-cas complexes
HK40060726A (en) Systems and methods for modulating crispr activity
HK40060724A (en) Stabilized crispr complexes
WO2026061453A1 (zh) 靶向系统及其应用
CA3230928A1 (en) Methods for using guide rnas with chemical modifications
CN118043465A (zh) 用于使用具有化学修饰的指导rna的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240628